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fComparative Determinants of 4-Year Cardiovascular Event Rates in
Stable Outpatients at Risk of or With Atherothrombosis
Bhatt DL, Eagle KA, Ohman EM, and the REACH Registry Investigators.
JAMA 2010;304:1350-7.
Conclusion: Patients with vascular events are those at highest risk for
future cardiovascular death, myocardial infarction, and stroke.
Summary: Clinical trials of pharmacologic agents in patients with
atherosclerosis often report event rates in placebo groups lower than pro-
jected (Bhatt DL, N Engl J Med 2009;361:2330-41; Sacco RL, N Engl
J Med 2008;359:1238-51; and Topol EG, Lancet 2010;376:517-23). To
increase likelihood that a particular therapy might demonstrate benefit, it is
important to identify patients to participate in trials who are at high risk for
cardiovascular events. The REACH (Reduction of Atherothrombosis for
Continued Health) Registry consists of patients with various manifestations
of atherosclerosis varying from asymptomatic adults with risk factors to those
with stable atherosclerosis to those with prior ischemic events. In this study
the authors analyze the effects of prior ischemic events, polyvascular disease,
and diabetes mellitus with respect to future cardiovascular risk. Patients in
the REACH Registry were followed for up to 4 years. Patients were from
3647 centers in 29 countries enrolled between 2003 and 2004 and followed
up until 2008. The primary end point was a composite of cardiovascular
deaths, myocardial infarction, and stroke. Main outcome measures were
rates of cardiovascular death, myocardial infarction, and stroke.
There were 45,227 patients included in the 4-year analysis. During
follow-up, 5481 patients experienced at least one event; 2315 cardiovascular
deaths, 1228 myocardial infarctions, 1898 strokes, and 40 cases where
myocardial infarction and stroke occurred on the same day. Those with a
history of ischemic events at baseline (n  21,890) had the highest rate of
subsequent ischemic events (18.3%: 95% confidence interval [CI], 17.4%-
19.1%). Patients with stable coronary, cerebrovascular, or peripheral artery
disease (n  15,264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%).
Patients with risk factors without established atherothrombosis (n  8073)
had the lowest risk (9.1%; 95%CI, 8.3%-9.9%; P .001 for all comparisons).
In multivariable modeling diabetes (hazard ratio [HR], 1.44; P .001), an
ischemic event in the previous year (HR 1.71; P  .01), and polyvascular
disease (HR, 1.99; P  .001) all were associated with increased risk of the
primary end point.
Comment: The data indicate polyvascular disease and a history of
ischemic events, particularly in the last year, are strongly associated with
cardiovascular death, myocardial infarction, and stroke. Many vascular sur-
gical patients would fall in to the high-risk groups. This perhaps explains, in
part, the high mortality rates of vascular surgical patients over time and
somewhat cynically may explain why vascular surgery patients tend to be
“repeat customers.” Once a patient with vascular disease has a cardiovascular
event they are much more likely to have additional events.
Standard Prophylactic Enoxaparin Dosing Leads to Inadequate
Anti-Xa Levels and Increased Deep Venous Thrombosis Rate in Criti-
cally Ill Trauma and Surgical Patients
Malinoski D, Jafari F, Ewing T. J Trauma 2010;68:874-80.
Conclusion: Standard prophylactic dosing of enoxaparin leads to low
anti-Xa levels in half of surgical intensive care unit patients with associated
increased risk of deep venous thrombosis (DVT).
Summary: DVT rates of those untreated intensive care unit (ICU)
patients range from 13% to 31% and up to 70% in severely injured patients.
Standard prophylaxis in higher-risk trauma or surgical patients includes
twice-daily dosing with enoxaparin (30 mg) but can still result in DVT rates
of 10% to 15%. Some patients experience altered pharmacokinetics and
pharmacodynamics of low-molecular-weight heparin (LMWH), reflected in
low trough anti-Xa levels with standard prophylactic dosing of LMWH. The
authors hypothesized that low anti-Xa levels would be found in critically ill,
trauma, and surgical patients treated with standard prophylactic doses of
LMWH and that such patients would have higher rates of DVT.
When there were no contraindications, surgical ICU patients were
treated with prophylactic enoxaparin and prospectively monitored. Anti-Xa
levels were drawn after the third dose. A trough level of0.01 IU/mL was
considered low. Screening venous duplex ultrasound exams were obtained at
48 hours of admission and then weekly. Excluded patients included those
who did not receive an ultrasound study, those who had a prior DVT, or if
anti-Xa trough levels were incorrectly obtained. Demographic data and
DVT rates were compared between patients with low and normal anti-Xa
levels. Fifty-four patients had a complete data set, of which 85% had an injury
severity score of 25  12. There were 74% men and 26% women, and 27
t
h
548atients (50%) had low anti-Xa levels. Those patients with low anti-Xa levels
ad more DVTs than those with normal levels (37% vs 11%, P  .026).
here were no differences between those with normal and low anti-Xa levels
ith respect to age, injury severity score, creatinine clearance, body mass
ndex, prevalence of high-risk injuries, and ICU/ventilator days.
Comment: The data provide at least a partial explanation for the
ontinued high rates of VTE complications in the injured patient despite
rotocols of chemical and mechanical VTE prophylaxis. It remains to be
een whether prophylactic dosing of LMWH stratified for anti-Xa levels
ould be both effective and cost effective in reducing VTE complications in
he injured patient or critically ill surgical patient.
andomized Clinical Trial of Mesh versus Sutured Wound Closure
fter Open Abdominal Aortic Aneurysm Surgery
evis PM, Windhaber RAJ, Lear PA, et al. Br J Surg 2010;97:1497-502.
Conclusion: Routine mesh placement reduces the rate of postopera-
ive incisional hernia after open abdominal aortic aneurysm (AAA) repair and
s not associated with increased complications.
Summary: There appears to be an increased risk of incisional hernia in
atients undergoing aortic surgery for an aneurysm compared with those
ndergoing aortic surgery for occlusive disease (Takagi H, Eur J Vasc
ndovasc Surg 2007;33:177-81). Rates of incisional hernia after AAA repair
ay be as high as 38% (Holland AJ, Eur J Vasc Endovasc Surg 1996;12:
96-200), and patients with AAA are postulated to have a connective tissue
isorder that increases susceptibility to incisional hernia (Adey B, Luna G,
m J Surg 1998;175:400-2). Prophylactic placement of prosthetic mesh in
he preperitoneal space during wound closure after open AAA repair may
esult in lower rates of incisional hernia (O’Hare JL, Eur J Vasc Endovasc
urg 2007;33;412-3).
The authors performed a randomized trial to see if mesh closure after
AA repair would result in fewer incisional hernias. Patients undergoing
pen AAA repair were randomized to routine abdominal mass closure or to
rophylactic placement of polypropylene mesh with abdominal wall closure.
he study included 85 patients (91% men) with a mean age of 73 years
range, 59-89 years). There were five perioperative deaths; none related to
esh. Hernia was determined by clinic examination or by ultrasound study.
uring follow-up, incisional hernia developed in 16 patients in the control
roup and in 5 in the mesh group (hazard ratio, 4.1; 95% confidence
nterval, 1.7.2-9.82; P .002). Hernia development occurred between 170
nd 585 days in the control group and between 336 and 1122 days in the
esh group. A minority of the hernias were repaired: four in the control
roup and one in the mesh group (P  .375). There were no mesh
nfections, but mesh was removed in one patient after seroma formation.
Comment: There are significant concerns regarding placement of
rophylactic polypropylene mesh. Certainly, mesh has been associated with
nfection and adhesion to underlying bowel. Although these complications
ere not noted in this series, the number of patients is small. The study does
onfirm a high rate of hernia formation in patients undergoing midline
ncisions for AAA repair and suggests hernia formation can be reduced by
rophylactic mesh replacement. The clinical significance of this is unclear
ecause the number of actual incisional hernia repairs was not statistically
ifferent in the patients undergoing routine mass closure vs those undergo-
ng prophylactic mass closure, implying many of the hernias perhaps were
mall or did not trouble the patient.
iabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of
ascular Disease: A Collaborative Meta-Analysis of 102 Prospective
tudies
he Emerging Risk Factors Coalition. Lancet 2010;375:2215-22.
Conclusion: Diabetes confers a twofold excess risk for a wide range of
ascular diseases. This is independent from other conventional risk factors.
asting blood glucose concentration in people without diabetes is also
odestly, but not linearly, associated with risk of vascular disease.
Summary: The authors used data from 121 prospective studies of
ascular risk factors involving individual records of 1.27 million adults. All
tudies had accrued 1 year of follow-up. They used these data to produce
stimates of the association of diabetes and fasting blood glucose concen-
rations with fatal or first ever nonfatal incident vascular disease (and deaths
rom other vascular disorders) under a wide range of conditions.
Analyses included data for 698,782 people. There were 52,765 nonfa-
al or fatal vascular outcomes over 8.49million person-years at risk. Adjusted
azard ratios (HRs) for diabetes were 2.00 (95% confidence interval [CI],
